{
  "first_published_at": "2014-11-17", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON468289", 
  "title": "Boceprevir (Victrelis) and telaprevir (Incivo): baseline predictive factors for sepsis, worsening liver function, and mortality", 
  "tags": "{\"parsed_therapeutic\": [\"gi-hepatology-pancreatic-disorders\", \"infectious-disease\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"GI, hepatology and pancreatic disorders\", \"Infectious disease\"]}", 
  "_document_number": 5, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "gi-hepatology-pancreatic-disorders", 
    "infectious-disease"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: November 2014</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Boceprevir and telaprevir are not recommended for patients who have a low platelet count or hypoalbuminaemia before starting either of these medicines. Boceprevir is also not recommended for patients who have coagulopathy before starting it.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Boceprevir (Victrelis) and telaprevir (Incivo) are protease inhibitors indicated for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease.</p>\n\n<p>A European review identified the following baseline markers as predictive factors for morbidity requiring hospitalisation (eg, sepsis, worsening liver function) and mortality in cirrhotic patients treated with either boceprevir or telaprevir in combination with peginterferon alfa and ribavirin: &#160;</p>\n\n<ul type=\"disc\">\n<li>low platelet count</li>\n\n<li>hypoalbuminaemia</li>\n\n<li>coagulopathy (for boceprevir only)</li>\n</ul>\n\n<p>Boceprevir and telaprevir are not recommended for patients who have a low platelet count or hypoalbuminaemia before starting either of these medicines. Boceprevir is also not recommended for patients who have coagulopathy before starting it. If treatment is started, closely monitor for infection, worsening liver function, and anaemia, as described in the summary of product characteristics (see below).</p>\n\n<p><strong>Further information</strong></p>\n\n<p><a target=\"_blank\" href=\"https://www.medicines.org.uk/emc/medicine/24768\">Boceprevir</a> summary of product characteristics</p>\n\n<p><a target=\"_blank\" href=\"https://www.medicines.org.uk/emc/medicine/25038\">Telaprevir </a>summary of product characteristics</p>\n\n<p><em>Article citation: Drug Safety Update volume 8 issue 4, November 2014: S1</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Boceprevir (Victrelis) and telaprevir (Incivo) are protease inhibitors indicated for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease.</p>\n\n<p>A European review identified the following baseline markers as predictive factors for morbidity requiring hospitalisation (eg, sepsis, worsening liver function) and mortality in cirrhotic patients treated with either boceprevir or telaprevir in combination with peginterferon alfa and ribavirin: &#160;</p>\n\n<ul type=\"disc\">\n<li>low platelet count</li>\n\n<li>hypoalbuminaemia</li>\n\n<li>coagulopathy (for boceprevir only)</li>\n</ul>\n\n<p>Boceprevir and telaprevir are not recommended for patients who have a low platelet count or hypoalbuminaemia before starting either of these medicines. Boceprevir is also not recommended for patients who have coagulopathy before starting it. If treatment is started, closely monitor for infection, worsening liver function, and anaemia, as described in the summary of product characteristics (see below).</p>\n\n<p><strong>Further information</strong></p>\n\n<p><a target=\"_blank\" href=\"https://www.medicines.org.uk/emc/medicine/24768\">Boceprevir</a> summary of product characteristics</p>\n\n<p><a target=\"_blank\" href=\"https://www.medicines.org.uk/emc/medicine/25038\">Telaprevir</a>summary of product characteristics</p>\n\n<p><em>Article citation: Drug Safety Update volume 8 issue 4, November 2014: S1</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2014-11-01", 
  "date_last_modified": "2014-11-17", 
  "_assets": [], 
  "_item_id": 5, 
  "summary": "", 
  "body": "Article date: November 2014\n\nBoceprevir (Victrelis) and telaprevir (Incivo) are protease inhibitors indicated for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease.\n\nA European review identified the following baseline markers as predictive factors for morbidity requiring hospitalisation (eg, sepsis, worsening liver function) and mortality in cirrhotic patients treated with either boceprevir or telaprevir in combination with peginterferon alfa and ribavirin: Â   \n  \n  * low platelet count  \n  * hypoalbuminaemia  \n  * coagulopathy (for boceprevir only)  \n  \nBoceprevir and telaprevir are not recommended for patients who have a low platelet count or hypoalbuminaemia before starting either of these medicines. Boceprevir is also not recommended for patients who have coagulopathy before starting it. If treatment is started, closely monitor for infection, worsening liver function, and anaemia, as described in the summary of product characteristics (see below).\n\nFurther information\n\n[Boceprevir](https://www.medicines.org.uk/emc/medicine/24768) summary of product characteristics\n\n[Telaprevir](https://www.medicines.org.uk/emc/medicine/25038)summary of product characteristics\n\nArticle citation: Drug Safety Update volume 8 issue 4, November 2014: S1\n"
}